The occurrence of a second primary cancer in a cancer survivor is well documented. It may be synchronous or metachronous. Incidence of metachronous cancer involving cervix is 0.82% to 1.33%. One such metachronous cancer is that of breast and cervix. We present a case of a woman who received tamoxifen for invasive ductal cancer of breast following a modified radical mastectomy and subsequently developed adenocarcinoma of cervix after six month of tamoxifen therapy. The role of tamoxifen in pathogenesis of cervical cancer and that of human papillomavirus infection in pathogenesis of both cancer of cervix and breast cancer has been well recognized. In our patient, the adenocarcinoma of cervix (rare occurrence) which is likely due to six month of tamoxifen therapy is a perplexing question. Women diagnosed and treated for breast cancer need to be followed up for development of other metachronous gynecological cancers. 
Introduction
The occurrence of a second primary cancer in a cancer survivor is well documented. It may be synchronous (within 6 months of diagnosis of first primary cancer) or metachronous (more than 6 months of diagnosis of first primary cancer). There may be several factors responsible for development of multiple primary malignancies like genetic predisposition and exposures to carcinogenic substances.
Treatment of first primary malignancy may lead to development of second cancer. The improvement in survival after a successful treatment of one cancer itself is a factor which increases the possibility of second primary malignancy. One such metachronous cancer is that of breast and cervix. Incidence of metachronous cancer involving cervix is 0.82% to 1.33%. 1 The other organs commonly involved are gastric, colon and lung. The histological type of cervical cancer in metachronous cancer is mostly squamous cell cancer and adenocarcinoma was rare. 1 The role of tamoxifen given for breast cancer in development of uterine and cervical cancer have been reported. But tamoxifen does not appear to endorse the pathogenesis of non-squamous cervical cancer. which is likely due to six month of tamoxifen therapy is a puzzling question. Women diagnosed and treated for breast cancer need to be followed up for development of other metachronous gynecological cancers.
